Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody.
We report that a-63-year-old woman developed Pneumocystis jiroveci pneumonia (PCP) as a complication from treatment with infliximab for rheumatoid arthritis. Although there was neither symptoms of dyspnea nor typical observations on a chest X-ray examination, low levels of oxygen saturation and findings of high-resolution chest computed tomographic scanning suggested a possibility of interstitial pneumonia. A polymerase chain reaction-based detection of Pneumocystis jiroveci in induced sputum allowed an early diagnosis of PCP and subsequent effective treatment.
Mori
Shunsuke
S
Division of Rheumatology, Department of Medicine, National Hospital Organization, Kumamoto Saishunso National Hospital, Suya 2659 Nishigohshi-machi, Kikuchi-gun, Kumamoto 860-1196, Japan. moris@saisyunsou.hosp.go.jp
Imamura
Fumiya
F
Kiyofuji
Chikage
C
Ito
Kanako
K
Koga
Yukinori
Y
Honda
Izumi
I
Sugimoto
Mineharu
M
D000890:Anti-Infective Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001785:Blood Gas Monitoring, Transcutaneous; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D000069285:Infliximab; D008875:Middle Aged; D045363:Pneumocystis carinii / Q000302:isolation & purification*; D011020:Pneumonia, Pneumocystis / Q000139:chemically induced* / Q000175:diagnosis; D014057:Tomography, X-Ray Computed; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000890:Anti-Infective Agents; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D000069285:Infliximab